Global biopharmaceutical company AbbVie has completed its acquisition of Allergan. The acquisition significantly expands and diversifies AbbVie’s product portfolio, which currently includes Humira, Skyrizi and Rinvoq under its Immunology umbrella, and Hematologic Oncology brands Imbruvica and Venclexta.
Carrie Strom will serve as senior vice president of AbbVie and president of Allergan Aesthetics. Additionally, the AbbVie board of directors has elected Thomas C. Freyman, retired executive vice president and CFO of Abbott and former member of the Allergan board of directors, to join the AbbVie board.
“We are pleased to reach this important milestone for the company, its employees, shareholders and the patients we serve,” said Richard A. Gonzalez, chairman and CEO of AbbVie. “Our new Allergan colleagues should be commended for all their efforts, along with those of our own employees, to achieve this turning point for our Company. The new AbbVie will be a well-diversified leader in many important therapeutic categories, with both on-market and pipeline assets, and our financial strength will allow us to continue to invest in innovative science and continue to serve unmet medical needs of patients that rely upon us. I am proud of both organizations and look forward to the opportunities ahead.”